PUBLICATION
Unveiling the anti-inflammatory potential of 11β,13-dihydrolactucin for application in inflammatory bowel disease management
- Authors
- Matos, M.S., Ávila-Gálvez, M.Á., González-Sarrías, A., Silva, N.V., Crespo, C.L., Jacinto, A., Serra, A.T., Matias, A.A., Nunes Dos Santos, C.
- ID
- ZDB-PUB-240821-1
- Date
- 2024
- Source
- Food & function 15(18): 9254-9271 (Journal)
- Registered Authors
- Keywords
- none
- MeSH Terms
-
- Animals
- Anti-Inflammatory Agents*/pharmacology
- Caco-2 Cells
- Cichorium intybus/chemistry
- Cyclooxygenase 2/genetics
- Cyclooxygenase 2/metabolism
- Disease Models, Animal
- HT29 Cells
- Humans
- Inflammatory Bowel Diseases*/drug therapy
- Interleukin-6/genetics
- Interleukin-6/metabolism
- Interleukin-8/genetics
- Interleukin-8/metabolism
- Lactones/pharmacology
- NF-kappa B/genetics
- NF-kappa B/metabolism
- Sesquiterpenes*/pharmacology
- Signal Transduction/drug effects
- Tumor Necrosis Factor-alpha/genetics
- Tumor Necrosis Factor-alpha/metabolism
- Zebrafish*
- PubMed
- 39162124 Full text @ Food Funct
Citation
Matos, M.S., Ávila-Gálvez, M.Á., González-Sarrías, A., Silva, N.V., Crespo, C.L., Jacinto, A., Serra, A.T., Matias, A.A., Nunes Dos Santos, C. (2024) Unveiling the anti-inflammatory potential of 11β,13-dihydrolactucin for application in inflammatory bowel disease management. Food & function. 15(18):9254-9271.
Abstract
Management of inflammatory bowel disease (IBD) poses significant challenges, and there is a need for innovative therapeutic approaches. This study investigates the anti-inflammatory properties of the dietary sesquiterpene lactone (SL) 11β,13-dihydrolactucin, which can be found in chicory, in three distinct complementary models of intestinal inflammation (two cell models and a zebrafish model), offering comprehensive insights into its potential application for IBD treatment alternatives. In a triple cell co-culture composed of Caco-2, HT29-MTX-E12, and Raji B, 11β,13-dihydrolactucin demonstrated remarkable anti-inflammatory activity at several levels of the cellular inflammatory response. Notably, 11β,13-dihydrolactucin prevented the activation of critical signalling pathways associated with inflammation, namely NF-κB and MAPK p38. This SL also decreased the release of the neutrophil-recruiting chemokine IL-8. Additionally, the compound reduced the gene expression of IL-6 and TNF-α, as well as the gene and protein expression of the inflammatory inducible enzymes iNOS and COX-2. In a myofibroblast-like human cell model, 11β,13-dihydrolactucin decreased the release of the cytokine TNF-α and the COX-2-derived inflammation mediator PGE2. Finally, in a zebrafish model of gut inflammation, 11β,13-dihydrolactucin effectively reduced neutrophil infiltration, further supporting its anti-inflammatory efficacy in a physiological context. Collectively, our findings highlight the promising anti-inflammatory potential of 11β,13-dihydrolactucin across various facets of intestinal inflammation, providing a foundation for the consideration of chicory as a promising candidate for incorporation in food or nutraceutical products for the potential prevention of IBD.
Genes / Markers
Expression
Phenotype
Mutations / Transgenics
Human Disease / Model
Sequence Targeting Reagents
Fish
Orthology
Engineered Foreign Genes
Mapping